Exenatide/insulin long acting - Hanmi Pharmaceutical

Drug Profile

Exenatide/insulin long acting - Hanmi Pharmaceutical

Alternative Names: LAPSInsulin Combo; LAPSInsulin115/LAPSCA-Exendine4; HM 14220; Insulin/exenatide long-acting - Hanmi Pharmaceutical; Long-acting insulin 115/exendin-4 combination - Hanmi Pharmaceutical

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (Parenteral)
  • 05 Nov 2015 GLP-1-RA/insulin drug combination licensed to Sanofi worldwide for the treatment of Type-2 diabetes mellitus
  • 01 Jun 2014 Preclinical trials in Type-2 diabetes mellitus in South Korea (Parenteral) before June 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top